News Sentiment

PMCB sentiment intelligence

PharmaCyte Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.70 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-2.6% over one week, -8.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader Conviction - Gap Down Bounce Plays

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -2.6% Price reacting lower
Trend fit Trend inactive -8.5% over four weeks
Fair value -54.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 37
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
TradingKey 9
TradingView 6
Market source 5
dars.gov.et 4
Moomoo 2
Intellectia AI 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 13
Regulatory and legal 3
Capital return 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-51 of 51
Stock Titan Direct company coverage

Director at PharmaCyte Biotech (PMCB) gets 119,170 options

PharmaCyte Biotech director Wayne Remell Walker has been granted 119,170 stock options with an exercise price of $0.67 per share, expiring on March 30, 2036. The options will fully vest on the date of the company's next annual meeting, provided Mr. Walker continues his service. T

Tone
Neutral 50/100
Event
Market update
Published
02 Apr 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67

PharmaCyte Biotech director Michael M. Abecassis was granted 119,170 stock options with an exercise price of $0.67 per share, expiring on March 30, 2036. These options will fully vest on the date of the company's next annual meeting, contingent on his continued service. This Form

Tone
Neutral 50/100
Event
Market update
Published
02 Apr 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Director Weinstein receives 119,170 stock options at PharmaCyte Biotech (PMCB)

PharmaCyte Biotech, Inc. reported that director Robert Weinstein received a grant of 119,170 stock options with an exercise price of $0.67 per share. These options, which expire on March 30, 2036, will vest in full upon the date of the company's next annual meeting of stockholder

Tone
Neutral 50/100
Event
Market update
Published
02 Apr 2026 22:10
Source
Stock Titan
TipRanks Direct company coverage

PharmaCyte Biotech Shareholders Approve Governance and Equity Actions

PharmaCyte Biotech shareholders approved key governance and equity actions during their annual meeting on March 30, 2026. These actions included the election of directors, ratification of their independent auditor, advisory approval of executive compensation, authorization for a

Tone
Neutral 50/100
Event
Regulatory and legal
Published
02 Apr 2026 21:10
Source
TipRanks
Stock Titan Direct company coverage

PharmaCyte Biotech (PMCB) wins approval for reverse split range and 2M new plan shares

PharmaCyte Biotech (PMCB) shareholders approved all five proposals at their annual meeting, including an amendment to the 2022 Equity Incentive Plan to increase shares available for awards by 2,000,000. They also granted the board discretionary authority to implement a reverse st

Tone
Neutral 50/100
Event
Regulatory and legal
Published
02 Apr 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

PharmaCyte Biotech 10-Q: $0.0M Revenue, $(0.17) EPS (Q3), $(2.41) EPS (YTD)

PharmaCyte Biotech reported no revenue for the three and nine months ended January 31, 2026, with a significant per-share loss of $(0.17) for the quarter and $(2.41) year-to-date. The company is actively engaged with the FDA regarding a clinical hold for pancreatic cancer and is

Tone
Negative 19/100
Event
Earnings
Published
17 Mar 2026 19:39
Source
TradingView
Stock Titan Direct company coverage

PharmaCyte Biotech (PMCB) seeks reverse split, equity plan boost at 2026 meeting

PharmaCyte Biotech (PMCB) will hold a virtual annual shareholder meeting on March 30, 2026, to vote on key corporate matters including the election of five directors, ratification of CBIZ CPAs P.C. as auditor, and an advisory vote on executive compensation. The company is also pr

Tone
Neutral 50/100
Event
Market update
Published
10 Mar 2026 08:09
Source
Stock Titan
Intellectia AI Direct company coverage

PMCB Should I Buy

An analysis of PharmaCyte Biotech Inc (PMCB) suggests it is not a strong buy opportunity for beginner, long-term investors. Despite some improvements in financial losses year-over-year, the company shows no revenue growth, weak overall financials, and mixed technical indicators l

Tone
Negative 38/100
Event
Earnings
Published
28 Feb 2026 04:51
Source
Intellectia AI
Stock Titan Direct company coverage

PharmaCyte Biotech (PMCB) seeks reverse split and 2M share plan boost at virtual meeting

PharmaCyte Biotech (PMCB) is holding a virtual annual meeting on March 30, 2026, to vote on several key proposals, including the election of five directors, ratification of CBIZ CPAs P.C. as auditor, and advisory approval of executive compensation. Critically, the company seeks s

Tone
Neutral 50/100
Event
Regulatory and legal
Published
27 Feb 2026 21:52
Source
Stock Titan
Stock Titan Direct company coverage

PMCB Financials: Income Statement, Balance Sheet & Cash Flow

This article provides a detailed financial overview of Pharmacyte Biotech Inc (PMCB) for fiscal year 2025, derived from SEC filings. It includes key financial metrics such as revenue, net income, EPS, cash & debt, and share buybacks, alongside the company's income statement, bala

Tone
Neutral 50/100
Event
Capital return
Published
25 Feb 2026 02:52
Source
Stock Titan